|
Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to M1 Kliniken AG
First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG (ISIN: DE000A0STSQ8) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 28,00. Zusammenfassung: Der Q2-Bericht hat erneut die wachsende Stärke des Injectables-Geschäfts von M1 gezeigt. Umsatz und EBIT des Beauty-Segments übertrafen FBe bei weitem, während die Ergebnisse des Handelssegments nahe an unseren Schätzungen lagen. In der Zwischenzeit verzeichneten die M1-Aktien am Dienstag einen beträchtlichen Kursanstieg, als das Management ein kurzes Update über das zuvor kommunizierte Interesse von Private Equity (PE) am Beauty-Geschäft von M1 gab und feststellte, dass sechs namhafte PE-Unternehmen Interesse an 'einer Beteiligung beziehungsweise an der Übernahme des Beauty-Segments' bekundet haben. Abgesehen von den Marktspekulationen hat das Beauty-Geschäft in letzter Zeit einen Aufschwung erlebt, und M1 ist auf dem besten Weg, unsere Ziele für 2024 zu übertreffen. Wir werden die Q3-KPIs aber abwarten, bevor wir unsere Schätzungen anpassen, und behalten unsere Kaufempfehlung mit einem unveränderten Kursziel von €28 bei. First Berlin Equity Research has published a research update on M1 Kliniken AG (ISIN: DE000A0STSQ8). Analyst Ellis Acklin reiterated his BUY rating and maintained his EUR 28.00 price target. Abstract: Q2 reporting once again showcased the growing strength of M1's injectables business. Beauty segment sales and EBIT overshot FBe by a wide margin, while Trade segment results were close to our estimates. Meanwhile, M1 shares caught a sizable bid on Tuesday when management gave a brief update on previously communicated private equity (PE) interest in M1's Beauty business, noting that six well-known PE outfits have expressed interest in 'investing in or acquiring the Beauty segment.' Market speculation aside, the Beauty business has been on a heater of late, and M1 is tracking slightly ahead of our 2024 targets. We will await Q3 KPI's before adjusting FBe and maintain our Buy rating with an unchanged €28 TP. Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse. You can download the research here: http://www.more-ir.de/d/30737.pdf Contact for questions: First Berlin Equity Research GmbH Herr Gaurav Tiwari Tel.: +49 (0)30 809 39 686 web: www.firstberlin.com E-Mail: g.tiwari@firstberlin.com
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
1983517 06.09.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
